Douglas Flora, Executive Medical Director of Yung Family Cancer Center at St. Elizabeth Healthcare, President-Elect of the Association of Cancer Care Centers, and Editor in Chief of AI in Precision Oncology, shared a post by John Fesko, President and Chief Business Officer
Natera, adding:
“The growing body of robust scientific evidence continues to reinforce my conviction that this represents a pivotal year for minimal residual disease (MRD) detection. We now have access to several hundred peer-reviewed clinical trials spanning more than a dozen tumor types, all demonstrating remarkably consistent findings.
The IMvigor011 results present compelling evidence that should fundamentally inform our clinical practice with these patient populations. In hematologic malignancies, we routinely make confident treatment decisions based on molecular response dynamics – it’s time we embrace these powerful diagnostic tools with equal rigor in solid tumor oncology.
This represents an exciting opportunity to advance precision medicine and improve patient outcomes through more sophisticated monitoring approaches
Congrats John Fesko, Adham Jurdi, John Fesko, Minetta Liu, Solomon Moshkevich on continued success.
This trial will help so many.”
Quoting John Fesko‘s post:
“15 years ago, seeing someone I love decline chemo for muscle-invasive bladder cancer sparked my interest in circulating tumor DNA. Today, Genentech’s Phase 3 Atezolizumab results, as Professor Thomas Powles notes, open the door to “a new treatment paradigm” for patients who are ‘positive for recurrence on a molecular level but have no evidence of disease on imaging.’ ”
More from Douglas Flora on OncoDaily.